Takemori Toshiyuki, Kawamoto Teruya, Hara Hitomi, Fukase Naomasa, Fujiwara Shuichi, Fujita Ikuo, Fujimoto Takuya, Morishita Masayuki, Kitayama Kazumichi, Yahiro Shunsuke, Miyamoto Tomohiro, Saito Masanori, Sugaya Jun, Hayashi Katsuhiro, Kawashima Hiroyuki, Torigoe Tomoaki, Nakamura Tomoki, Kondo Hiroya, Wakamatsu Toru, Watanuki Munenori, Kito Munehisa, Tsukushi Satoshi, Nagano Akihito, Outani Hidetatsu, Toki Shunichi, Nishimura Shunji, Kobayashi Hiroshi, Watanabe Itsuo, Demizu Yusuke, Sasaki Ryohei, Fukumoto Takumi, Niikura Takahiro, Kuroda Ryosuke, Akisue Toshihiro
Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan.
Cancers (Basel). 2022 Jun 20;14(12):3023. doi: 10.3390/cancers14123023.
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
本研究旨在回顾性分析盆腔及腹膜后骨与软组织肉瘤（BSTS）患者的临床结局。总体而言，纳入了日本19家专业肉瘤中心治疗的187例盆腔及腹膜后区域的BSTS患者。评估了与总生存期（OS）、局部控制（LC）和无进展生存期（PFS）相关的预后因素。187例患者的3年OS率和LC率分别为71.7%和79.1%。166例在原发性肿瘤诊断时无任何远处转移的患者的3年PFS为48.6%。骨肉瘤的OS和PFS明显低于盆腔及腹膜后其他肉瘤。在单因素分析中，原发性肿瘤体积较大、软组织肿瘤、原发性肿瘤诊断时的远处转移、P2位置、化疗和骨肉瘤是与OS相关的不良预后因素。在初始表现时无任何转移的患者中，原发性肿瘤体积较大、年龄较大、软组织肿瘤、化疗和骨肉瘤是与PFS相关的不良预后因素。原发性肿瘤体积较大是与LC相关的唯一不良预后因素。本研究阐明了日本盆腔及腹膜后BSTS患者的流行病学和预后情况。
Zotero 插件